Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls

2016 ◽  
Vol 39 (8) ◽  
pp. 855-863 ◽  
Author(s):  
P. Wanby ◽  
R. Nobin ◽  
S.-P. Von ◽  
L. Brudin ◽  
M. Carlsson
Keyword(s):  
Hip Fracture ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Geriatric Patients ◽  
Serum Levels ◽  
Healthy Controls ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Turnover Markers ◽  
Dickkopf 1

Predictors and relationships of serum 25 hydroxyvitamin D concentration with bone turnover markers, bone mineral density, and vitamin D receptor genotype in Emirati women

Bone ◽  
2006 ◽  
Vol 39 (5) ◽  
pp. 1136-1143 ◽  
Author(s):  
Hussein F. Saadi ◽  
Nicolaas Nagelkerke ◽  
Sheela Benedict ◽  
Hussein S. Qazaq ◽  
Erica Zilahi ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Bone Turnover ◽  
Bone Mineral ◽  
Vitamin D Receptor ◽  
Bone Turnover Markers ◽  
Mineral Density ◽  
Hydroxyvitamin D ◽  
25 Hydroxyvitamin D ◽  
Turnover Markers

Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis

2011 ◽  
Vol 71 (1) ◽  
pp. 71-74 ◽  
Author(s):  
L Senolt ◽  
H Hulejova ◽  
O Krystufkova ◽  
S Forejtova ◽  
L Andres Cerezo ◽  
...  
Keyword(s):  
Bone Formation ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Diffuse Idiopathic Skeletal Hyperostosis ◽  
Serum Levels ◽  
Total Serum ◽  
Mineral Density ◽  
Spinal Involvement ◽  
Turnover Markers ◽  
Dickkopf 1

ObjectiveDickkopf-1 (DKK-1) is an inhibitor of osteoblastogenesis, and its lower levels are linked to new bone formation. The aim of this study was therefore to explore serum levels of DKK-1 and to evaluate DKK-1's association with the severity of spinal involvement in diffuse idiopathic skeletal hyperostosis (DISH).MethodsSerum levels of total and functional DKK-1 and C-reactive protein (CRP) were measured in 37 patients with DISH and 22 healthy age and sex-matched controls. Plain radiographs of the cervical and thoracic spine were performed, and the diagnosis of DISH was defined using the Resnick criteria. Patients were divided into three groups based on spinal involvement. Bone mineral density (BMD) and bone turnover markers were evaluated in patients with DISH.ResultsThe levels of total serum DKK-1 were significantly lower in patients with DISH than in healthy controls (p<0.0001). Importantly, low serum levels of DKK-1 were associated with more severe spinal involvement in DISH, independent of age, sex, disease duration, CRP, bone turnover markers or BMD. However, these findings were less significant for functional DKK-1.ConclusionThese observations indicate that DKK-1 may play a significant role in bone formation during DISH.

Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease

2019 ◽  
Vol 49 (4) ◽  
pp. 284-293 ◽  
Author(s):  
Stephen A. Strugnell ◽  
Stuart M. Sprague ◽  
Akhtar Ashfaq ◽  
Martin Petkovich ◽  
Charles W. Bishop
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Clinical Practice ◽  
Bone Turnover ◽  
Bone Turnover Markers ◽  
Hydroxyvitamin D ◽  
Calcium Phosphorus ◽  
Safety Parameters ◽  
25 Hydroxyvitamin D ◽  
Turnover Markers

Background: Vitamin D repletion is recommended for secondary hyperparathyroidism (SHPT) and associated vitamin D insufficiency (VDI) in chronic kidney disease (CKD), but optimal levels of serum total 25-hydroxyvitamin D remain undefined. Clinical practice guidelines target sufficiency, whereas recent data indicate that higher levels are required to control the elevation of intact parathyroid hormone (iPTH) as CKD advances. This secondary analysis of 2 randomized controlled trials seeks to identify the minimum level of mean serum 25-hydroxyvitamin D required to control SHPT arising from VDI in stage 3 or 4 CKD. Methods: Adult subjects (n = 429) with SHPT, VDI, and stage 3 or 4 CKD were stratified by stage and treated daily with either extended-release calcifediol (ERC) or placebo in 2 identical, parallel, randomized, double-blind studies. After treatment for 26 weeks, all subjects were ranked by the level of serum total 25-hydroxyvitamin D and divided into quintiles in order to examine the relationships between the degree of vitamin D repletion and the associated changes in plasma iPTH, serum bone turnover markers, calcium, phosphorus, intact fibroblast growth factor 23 (FGF23) and vitamin D metabolites, estimated glomerular filtration rate (eGFR), and urine calcium:creatinine (Ca:Cr) ratio. Results: Progressive increases in serum 1,25-dihydroxyvitamin D and reductions in plasma iPTH and serum bone turnover markers were observed as mean posttreatment serum 25-hydroxyvitamin D rose from 13.9 ng/mL (in Quintile 1) to 92.5 ng/mL (in Quintile 5), irrespective of CKD stage. Mean serum calcium, phosphorus and FGF23, eGFR, and urine Ca:Cr ratio (collectively “safety parameters”) did not significantly change from Quintile 1. Suppression of iPTH and bone turnover markers was not observed until serum 25-hydroxyvitamin D rose to at least 50.8 ng/mL (Quintile 3). Conclusion: ERC therapy produced exposure-dependent reductions in plasma iPTH and bone turnover markers only when mean serum total 25-hydroxyvitamin D reached at least 50.8 ng/mL, indicating that current targets for vitamin D repletion therapy in CKD are too low. Gradual elevation of mean serum 25-hydroxyvitamin D to 92.5 ng/mL was not associated with significant adverse changes in safety parameters.

Serum levels of the bone turnover markers dickkopf-1, osteoprotegerin, and TNF-α in knee osteoarthritis patients

2017 ◽  
Vol 36 (10) ◽  
pp. 2351-2358 ◽  
Author(s):  
Sicong Min ◽  
Chao Wang ◽  
Wanli Lu ◽  
Zhihong Xu ◽  
Dongquan Shi ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Knee Osteoarthritis ◽  
Bone Turnover Markers ◽  
Serum Levels ◽  
Tnf Α ◽  
Turnover Markers ◽  
Dickkopf 1

scholarly journals Immediate changes in biochemical markers of bone turnover and circulating interleukin-6 after parathyroidectomy for primary hyperparathyroidism

2000 ◽  
pp. 451-459 ◽  
Author(s):  
CY Guo ◽  
PA Holland ◽  
BF Jackson ◽  
RA Hannon ◽  
A Rogers ◽  
...  
Keyword(s):  
Primary Hyperparathyroidism ◽  
Bone Turnover ◽  
Interleukin 6 ◽  
Bone Turnover Markers ◽  
Biochemical Markers ◽  
Time Course ◽  
Serum Levels ◽  
Healthy Controls ◽  
Markers Of Bone Turnover ◽  
Turnover Markers

OBJECTIVE: The time course of the immediate change in bone turnover after parathyroidectomy (PTX) for primary hyperparathyroidism (PHPT) is not clear. It is uncertain whether circulating interleukin-6 (IL-6) plays a role in mediating the acute withdrawal of the effects of parathyroid hormone (PTH) on bone turnover after PTX. The aims of this study were to determine the time course of immediate changes in biochemical markers of bone turnover after PTX and whether circulating IL-6 is involved in the immediate changes of bone turnover after PTX. DESIGN AND METHODS: IL-6 and bone turnover markers were measured in eight women (aged 55+/-11 years, mean+/-s.d. ) with PHTP at baseline and at 1-2h, and 1, 2, 5, 7 and 12 days after PTX. We compared the results with those from eight individually matched women (healthy controls) and five subjects undergoing major surgery (surgical controls). RESULTS: At baseline, serum levels of IL-6 and bone turnover markers were higher in PHPT than those in healthy controls (P<0.05). Serum levels of procollagen propeptides increased by 22 and 27% at days 2 and 5, respectively, compared with baseline (P<0.05). Serum tartrate-resistant acid phosphatase decreased by 2 days after PTX, and urinary collagen crosslinks decreased significantly by 21-41% within 24h (P<0.05). Serum IL-6 levels increased immediately in both PHPT and surgical controls at postoperative follow-up (repeated measures ANOVA). CONCLUSIONS: (1) PTX decreases bone resorption immediately and (2) circulating IL-6 is not involved in the changes in bone turnover immediately after PTX.

Sign in / Sign up

Export Citation Format

Share Document